NVNO News and Press, enVVeno Medical Corp Com From 03/15/24

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21 st at 12:00 PM ET IRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatm...

2024-03-06 17:59:20 ET Summary enVVeno Medical Corporation has released remarkably positive topline data from its pivotal trial for the VenoValve. The path to file for approval in Q4 2024 seems open. The VenoValve targets a significant market of 2.5 million patients in the US ...

2024-03-06 10:00:12 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS)) 74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points) Averag...

$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March ...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...